Drug Induced Interstitial Lung Disease
Martin Schwaiblmair*, 1, Werner Behr2, Thomas Haeckel3, Bruno Märkl4, Wolfgang Foerg5, Thomas Berghaus1
Identifiers and Pagination:Year: 2012
First Page: 63
Last Page: 74
Publisher ID: TORMJ-6-63
Article History:Received Date: 4/5/2012
Revision Received Date: 6/7/2012
Acceptance Date: 6/7/2012
Electronic publication date: 27/7/2012
Collection year: 2012
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease (DILD) can be caused by chemotherapeutic agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. There are no distinct physiologic, radiographic or pathologic patterns of DILD, and the diagnosis is usually made when a patient with interstitial lung disease (ILD) is exposed to a medication known to result in lung disease. Other causes of ILD must be excluded. Treatment is avoidance of further exposure and systemic corticosteroids in patients with progressive or disabling disease.